Dr. Shur is a dynamic R&D executive with nearly two decades of experience leading groundbreaking initiatives in the pharmaceutical industry. Throughout his career, he has been at the forefront of developing complex dosage forms, launching new drug delivery and analytical platforms, and founding successful start-up biotech businesses. His innovative approach to problem-solving has enabled him to achieve remarkable success, including the successful exit of his start-ups. With a proven track record of delivering results, Dr. Shur is a visionary leader who is always looking to push the boundaries of what is possible in pharmaceutical R&D.
His main area of research and commercial endeavor is in the complex topical pharmaceutical drug products area. A key theme of his research and commercial enterprises have been to develop patient-centric drug development platforms. Dr. Shur began his career with Profile Drug Delivery (now Philips Respironics) where he developed liquid dose drug delivery systems for cystic fibrosis patients, and later went on to work for GlaxoSmithKline.
Dr. Shur holds a BSc (Hons) in Chemistry and completed his PhD, entitled ‘Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis’. Following this, he was a post-doctoral fellow at the London School of Pharmacy, investigating the fabrication of microparticles for vaccine delivery using supercritical fluid technology. Dr. Shur has published several scientific articles and is also the inventor on many patents.